About all

Elevated Liver Tests Causes: Understanding Liver Function Tests

by alexxlab

What causes elevated liver tests? Discover the common reasons for abnormal liver function test results, including liver infections, medication side effects, and more. Get informed on the different types of liver tests and how to interpret the results.

Exploring the Causes of Elevated Liver Tests

Liver function tests are a crucial tool for monitoring the health of your liver. These blood tests measure the levels of various proteins, enzymes, and bilirubin in the blood, providing valuable insights into the liver’s performance. Elevated liver tests can indicate a range of underlying issues, from liver infections and medication side effects to chronic liver diseases and more. In this comprehensive article, we’ll delve into the common causes of elevated liver tests and explore the different types of liver function tests used to assess liver health.

Understanding Liver Function Tests

Liver function tests, also known as liver chemistries, are a group of blood tests that help determine the overall health of the liver. These tests measure the levels of specific proteins, enzymes, and bilirubin in the blood, which can provide clues about the liver’s function. Doctors may recommend these tests to screen for liver diseases, monitor the side effects of medications, or examine the severity of an existing liver condition.

Common Types of Liver Function Tests

Some of the most commonly performed liver function tests include:

  • Alanine Transaminase (ALT) Test: ALT is an enzyme found in the liver, and elevated levels can indicate liver damage or dysfunction.
  • Aspartate Aminotransferase (AST) Test: AST is an enzyme found in various organs, including the liver, and can also be a marker of liver injury.
  • Alkaline Phosphatase (ALP) Test: ALP is an enzyme found in the bile ducts, bones, and liver, and an elevated level may suggest a problem with the bile duct system or liver.
  • Albumin Test: Albumin is a protein produced by the liver and plays a crucial role in various bodily functions. A low albumin level can indicate liver dysfunction.
  • Bilirubin Test: Bilirubin is a waste product from the breakdown of red blood cells, and an elevated level may signify a problem with the liver’s ability to process bilirubin.

Interpreting Liver Function Test Results

What do the results of liver function tests mean? Generally, higher-than-typical levels of these enzymes or proteins can indicate a problem with the liver, while lower-than-typical levels may also suggest liver dysfunction. However, it’s important to note that the specific interpretation of these test results can vary depending on the individual’s overall health and medical history. After any liver function test, it’s crucial to discuss the results with your healthcare provider to determine the underlying cause and appropriate next steps.

Reasons for Elevated Liver Tests

There are several common causes of elevated liver tests, including:

  1. Liver Infections: Viral hepatitis, such as hepatitis B and hepatitis C, can cause inflammation and damage to the liver, leading to elevated liver enzyme levels.
  2. Medication Side Effects: Certain medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), statins, antibiotics, and tuberculosis drugs, can sometimes have a negative impact on liver function and cause elevated liver tests.
  3. Existing Liver Diseases: Conditions like fatty liver disease, cirrhosis, and other chronic liver diseases can cause ongoing liver dysfunction, which can be monitored through regular liver function tests.
  4. Alcohol Consumption: Frequent or heavy alcohol use can have a detrimental effect on the liver, contributing to elevated liver enzyme levels.
  5. Certain Medical Conditions: Conditions such as high triglycerides, diabetes, high blood pressure, and anemia can also be associated with elevated liver tests.
  6. Gallbladder Disease: Issues with the gallbladder, such as gallstones, can sometimes lead to elevated liver enzyme levels.
  7. Genetic Disorders: Inherited conditions that affect the liver, such as Wilson’s disease or Gilbert’s syndrome, can also cause abnormal liver function test results.

Symptoms of Liver Disorders

If you have elevated liver tests, what symptoms might you experience? Common signs of a liver disorder include:

  • Weakness and fatigue
  • Unintentional weight loss
  • Jaundice (yellowing of the skin and eyes)
  • Fluid accumulation in the abdomen (ascites)
  • Discolored urine or stool

It’s important to note that some individuals with liver disorders may not experience any noticeable symptoms, particularly in the early stages of the disease. Regular monitoring through liver function tests can help detect liver problems before they become more severe.

Seeking Medical Attention

If you have elevated liver tests, it’s crucial to follow up with your healthcare provider. They will work with you to determine the underlying cause and develop an appropriate treatment plan. Depending on the suspected cause, your doctor may order additional tests, such as imaging scans or liver biopsies, to get a clearer picture of your liver health.

Remember, problems with the liver can have serious consequences and should not be taken lightly. By understanding the causes of elevated liver tests and seeking prompt medical attention, you can take proactive steps to address any liver-related issues and maintain your overall health.

Liver Function Tests: Purpose, Procedure, and Results

Liver function tests are blood tests that can be used to monitor the health of your liver. Ask the doctor what you need to do to prepare. In some cases you may need to avoid food or certain medications before the test.

Liver function tests, also known as liver chemistries, help determine the health of your liver by measuring the levels of proteins, liver enzymes, and bilirubin in your blood. They can also monitor the progression or treatment of an existing disease.

Depending on the test, either higher- or lower-than-typical levels of these enzymes or proteins can indicate a problem with your liver.

Some of the reasons liver function tests may be performed include screening for diseases such as hepatitis, monitoring the side effects of your medications, and examining the severity of liver disease.

In this article, we take a look at when you might need a liver function test, the different types of tests used, and how to interpret results.

A liver function test is often recommended in the following situations:

  • to check for damage from liver infections, such as hepatitis B and hepatitis C, especially if it’s suspected you were exposed to a virus that causes hepatitis
  • to monitor the side effects of certain medications because some medications are known to affect the liver, including:
    • NSAIDs
    • statins
    • antibiotics
    • antiseizure medications
    • tuberculosis drugs
  • if you already have liver disease, to monitor the disease and how well a particular treatment is working
  • if you’re experiencing the symptoms of a liver disorder or have a family history of a liver disease, such as fatty liver disease
  • if you have certain medical conditions, such as:
    • high triglycerides
    • diabetes
    • high blood pressure
    • anemia
  • if you drink alcohol frequently
  • if you have gallbladder disease

Certain tests can reflect different aspects of liver function. For example, elevated alanine transaminase and aspartate transaminase disproportional to bilirubin and alkaline phosphatase levels often indicates liver disease.

Liver function tests are used to measure specific enzymes and proteins in your blood.

Having atypical results on any of these liver tests usually requires a follow-up to determine the cause of the atypical characteristics. Even mildly elevated results can be associated with liver disease.

Common liver function tests include:

Alanine transaminase (ALT) test

Alanine transaminase (ALT) is used by your body to metabolize protein. If the liver is damaged or not functioning properly, ALT can be released into the blood. This causes ALT levels to increase. A higher result than what’s typical on this test can be a sign of liver damage.

It’s estimated that about 10 percent of people in the United States have elevated ALT levels.

Aspartate aminotransferase (AST) test

Aspartate aminotransferase (AST) is an enzyme found in several parts of your body, including your:

  • heart
  • brain
  • pancreas
  • liver
  • muscles

When the liver is damaged, AST can be released into the bloodstream. A high result on an AST test might indicate a problem with the liver or muscles.

Since AST levels aren’t as specific of a marker for liver damage as ALT, it’s usually measured together with ALT to check for liver problems. For example, a high AST:ALT ratio may indicate alcoholic liver disease.

Alkaline phosphatase (ALP) test

Alkaline phosphatase (ALP) is an enzyme found in your bones, bile ducts, and liver. An ALP test is typically ordered in combination with several other tests. An ALP test can be used to evaluate the bile duct system of the liver.

Albumin test

Albumin is the main protein made by your liver. It performs many important bodily functions.

For example, albumin nourishes your tissues and transports hormones, vitamins, and other substances throughout your body. An albumin test measures how well your liver is making this particular protein.

Bilirubin test

Bilirubin is a waste product from the breakdown of red blood cells. It’s ordinarily processed by the liver. It passes through the liver before being excreted through your stool.

A damaged liver can’t properly process bilirubin. This leads to an atypically high level of bilirubin in the blood. Certain inherited diseases can raise bilirubin levels, even when liver function works as expected.

The following table shows what liver function tests may indicate in terms of higher or lower results than typical. Following any liver function test, you should have a discussion with your doctor about your test results and what they mean for you.

Problems with the liver can make a person very sick and can even be life threatening. Approximately 4.5 million adults in the United States have chronic liver disease.

Symptoms of a liver disorder include:

  • weakness
  • fatigue or loss of energy
  • weight loss
  • jaundice (yellow skin and eyes)
  • fluid collection in the abdomen, known as ascites
  • discolored bodily discharge (dark urine or light stools)
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • atypical bruising or bleeding

Your doctor may order a liver function test if you’re experiencing symptoms of a liver disorder.

Liver function tests can also monitor the progression or treatment of a disease and test for the side effects of certain medications.

Your doctor will give you complete instructions on how to prepare for the blood sample portion of the test.

Certain medications and foods may affect levels of these enzymes and proteins in your blood. Your doctor may ask you to avoid some types of medications, or they may ask you to avoid eating anything for a period of time before the test. Be sure to continue drinking water prior to the test.

You may want to wear a shirt with sleeves that can easily be rolled up to make it easier for the medical expert to collect the blood sample.

You may have your blood drawn in a hospital or at a specialized testing facility. To administer the test:

  1. The healthcare technician will clean your skin before the test to decrease the likelihood that any microorganisms on your skin will cause an infection.
  2. They’ll likely wrap an elastic strap on your arm. This will help your veins become more visible. They’ll then use a needle to draw samples of blood from your arm.
  3. After the draw, the technician will place some gauze and a bandage over the puncture site. Your blood sample will be sent to a laboratory for testing.

Potential risks of a liver function test

Blood draws are routine procedures and rarely cause any serious side effects. However, the risks of giving a blood sample can include:

  • bleeding under the skin, or hematoma
  • excessive bleeding
  • fainting
  • infection

Was this helpful?

After the test, you can usually resume everyday activities. However, if you feel faint or lightheaded during the blood draw, you should rest before you leave the testing facility.

The results of these tests may not tell your doctor exactly which condition you have or the degree of liver damage, but they might help your doctor determine the next steps. Your doctor will call you with the results or discuss them with you at a follow-up appointment.

In general, if your results indicate a problem with your liver function, your doctor will review your medications and your past medical history to help determine the cause.

If you drink alcohol frequently, then you’ll need to stop drinking it. If your doctor identifies that a medication is causing the elevated liver enzymes, they’ll advise you to stop the medication.

Other diagnostic tests

Your doctor may decide to test you for hepatitis, other infections, or other diseases that can affect the liver. They may also choose to do imaging tests, like an ultrasound or CT scan.

In addition, they may recommend a liver biopsy to evaluate the liver for fibrosis, fatty liver disease, or other liver conditions.

Liver function tests are blood tests used to help determine the health of your liver. Changes in certain levels of proteins or enzymes can alert doctors of potential problems such as liver cancer, fatty liver disease, or hepatitis.

Liver function tests can also help determine if certain medications are damaging your liver or help you monitor the progression of liver disease.

After you get a liver function test, your doctor can help you interpret the results and discuss what the results mean for you. If they suspect you have liver disease, you may need to undergo other tests such as imaging or a liver biopsy.

Elevated Liver Enzymes in Asymptomatic Patients – What Should I Do?

1. Hultcrantz R, Glaumann H, Lindberg G, Nilsson LH. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol. 1986;21:109–113. 10.3109/00365528609034632. [PubMed] [Google Scholar]

2. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999–2002. Am J Gastroenterol. 2006;101:76–82. 10.1111/j.1572-0241.2005.00341.x. [PubMed] [Google Scholar]

3. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112:18–35. 10.1038/ajg.2016.517. [PubMed] [Google Scholar]

4. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem. 2000;46:2050–2068. [PMC free article] [PubMed] [Google Scholar]

5. Dufour DR. Effects of habitual exercise on routine laboratory tests. Clin Chem. 1998;44:A136. [Google Scholar]

6. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123:1367–1384. 10.1053/gast.2002.36061. [PubMed] [Google Scholar]

7. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342:1266–1271. 10.1056/NEJM200004273421707. [PubMed] [Google Scholar]

8. Gopal DV, Rosen HR. Abnormal findings on liver function tests. Interpreting results to narrow the diagnosis and establish a prognosis. Postgrad Med. 2000;107:100–114. 10.3810/pgm.2000.02.869. [PubMed] [Google Scholar]

9. Friedman LS, Dienstag JL, Watkins E, Hinkle CA, Spiers JA, Rieder SV, et al. Evaluation of blood donors with elevated serum alanine aminotransferase levels. Ann Intern Med. 1987;107:137–144. 10.7326/0003-4819-107-2-137. [PubMed] [Google Scholar]

10. Hay JE, Czaja AJ, Rakela J, Ludwig J. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology. 1989;9:193–197. 10.1002/hep.1840090205. [PubMed] [Google Scholar]

11. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol. 1999;94:3010–3014. 10.1111/j.1572-0241.1999.01451.x. [PubMed] [Google Scholar]

12. Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol. 2002;97:2714–2724. 10.1111/j.1572-0241.2002.07069.x. [PubMed] [Google Scholar]

13. Aragon G, Younossi ZM. When and how to evaluate mildly elevated liver enzymes in apparently healthy patients. Cleve Clin J Med. 2010;77:195–204. 10.3949/ccjm.77a.09064. [PubMed] [Google Scholar]

14. Rude MK, Kerr T, Lisker-Melman M. Liver diseases. In: Godara H, Hirbe A, Nassif M, Otepka H, Rosenstock A, editors. The washington manual of medical therapeutics. 34th Edition. Washington: Lippincott Williams & Wilkins; 2014. pp. 664–721. [Google Scholar]

15. Verslype C. Evaluation of abnormal liver-enzyme results in asymptomatic patients. Acta Clin Belg. 2004;59:285–289. 10.1179/acb.2004.042. [PubMed] [Google Scholar]

16. Das A, Post AB. Should liver biopsy be done in asymptomatic patients with chronically elevated transaminases: A costutility analysis. Gastroenterology. 1998;114:A9. 10.1016/S0016-5085(98)80035-8. [Google Scholar]

17. Sorbi D, McGill DB, Thistle JL, Therneau TM, Henry J, Lindor KD. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol. 2000;95:3206–3210. 10.1111/j.1572-0241.2000. 03293.x. [PubMed] [Google Scholar]

18. Cohen JA, Kaplan MM. The SGOT/SGPT ratio–an indicator of alcoholic liver disease. Dig Dis Sci. 1979;24:835–838. 10.1007/BF01324898. [PubMed] [Google Scholar]

19. Diehl AM, Potter J, Boitnott J, Van Duyn MA, Herlong HF, Mezey E. Relationship between pyridoxal 5’-phosphate deficiency and aminotransferase levels in alcoholic hepatitis. Gastroenterology. 1984;86:632–636. [PubMed] [Google Scholar]

20. Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol. 2005;3:1260–1268. 10.1016/S1542-3565(05)00743-3. [PubMed] [Google Scholar]

21. Alter HJ. To C or not to C: these are the questions. Blood. 1995;85:1681–1695. [PubMed] [Google Scholar]

22. Everhart JE. Digestive diseases in the United States: Epidemiology and impact. Maryland: NIH Publication; 1994. pp. 94–1447. [Google Scholar]

23. Dancygier H, Rogart JN. Approach to the patient with abnormal liver enzymes. In: Dancygier H, editor. Clinical hepatology. Verlag Berlin Heidelberg: Springer; 2010. pp. 533–547. 10.1007/978-3-540-93842-2_49. [Google Scholar]

24. Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol. 2008;48:743–746. 10.1016/j.jhep.2008.01.023. [PubMed] [Google Scholar]

25. Schiff ER, de Medina M, Kahn RS. New perspectives in the diagnosis of hepatitis C. Semin Liver Dis. 1999;19(Suppl 1):3–15. [PubMed] [Google Scholar]

26. Halfon P, Bourlière M, Pénaranda G, Khiri H, Ouzan D. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. J Clin Microbiol. 2006;44:2507–2511. 10.1128/JCM.00163-06. [PMC free article] [PubMed] [Google Scholar]

27. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172:367–379. 10.1503/cmaj.1040752. [PMC free article] [PubMed] [Google Scholar]

28. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology. 1988;95:734–739. 10.1016/S0016-5085(88)80022-2. [PubMed] [Google Scholar]

29. Giannini E, Botta F, Fasoli A, Ceppa P, Risso D, Lantieri PB, et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci. 1999;44:1249–1253. 10.1023/A:1026609231094. [PubMed] [Google Scholar]

30. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. 2003;163:218–224. 10.1001/archinte.163.2.218. [PubMed] [Google Scholar]

31. Giannini E, Botta F, Testa E, Romagnoli P, Polegato S, Malfatti F, et al. The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis. Am J Gastroenterol. 2002;97:2855–2860. 10.1111/j.1572-0241.2002.07053.x. [PubMed] [Google Scholar]

32. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94:1018–1022. 10.1111/j.1572-0241.1999.01006.x. [PubMed] [Google Scholar]

33. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103–1109. 10.1016/0016-5085(94)90235-6. [PubMed] [Google Scholar]

34. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis. 2004;24:3–20. 10.1055/s-2004-823098. [PubMed] [Google Scholar]

35. Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology. 1988;95:1056–1062. 10.1016/0016-5085(88)90183-7. [PubMed] [Google Scholar]

36. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–1362. 10.1002/hep.510300604. [PubMed] [Google Scholar]

37. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–1292. 10.1053/jhep.2003.50229. [PubMed] [Google Scholar]

38. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–1419. 10.1016/S0016-5085(99)70506-8. [PubMed] [Google Scholar]

39. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand. 1986;220:83–88. 10.1111/j. 0954-6820.1986.tb02733.x. [PubMed] [Google Scholar]

40. Lavine JE. Treatment of obesity-induced steatohepatitis with vitamin E. Gastroenterology. 1998;114:A1284–A1285. 10.1016/S0016-5085(98)85214-1. [Google Scholar]

41. Powell LW, George DK, McDonnell SM, Kowdley KV. Diagnosis of hemochromatosis. Ann Intern Med. 1998;129:925–931. 10.7326/0003-4819-129-11_Part_2-199812011-00002. [PubMed] [Google Scholar]

42. Tavill AS, American Association for the Study of Liver Diseases. American College of Gastroenterology. American Gastroenterological Association Diagnosis and management of hemochromatosis. Hepatology. 2001;33:1321–1328. 10.1053/jhep.2001.24783. [PubMed] [Google Scholar]

43. Guyader D, Jacquelinet C, Moirand R, Turlin B, Mendler MH, Chaperon J, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology. 1998;115:929–936. 10.1016/S0016-5085(98)70265-3. [PubMed] [Google Scholar]

44. Morrison ED, Kowdley KV. Genetic liver disease in adults. Early recognition of the three most common causes. Postgrad Med. 2000;107:147–159. 10.3810/pgm.2000.02.872. [PubMed] [Google Scholar]

45. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 1996;334:897–903. 10.1056/NEJM199604043341406. [PubMed] [Google Scholar]

46. Manns MP, Bahr MJ. Recurrent autoimmune hepatitis after liver transplantation-when non-self becomes self. Hepatology. 2000;32:868–870. 10.1053/jhep.2000.19149. [PubMed] [Google Scholar]

47. Czaja AJ. Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis. 1984;4:1–12. 10.1055/s-2008-1040641. [PubMed] [Google Scholar]

48. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938. 10.1016/S0168-8278(99)80297-9. [PubMed] [Google Scholar]

49. Limdi JK, Hyde GM. Evaluation of abnormal liver function tests. Postgrad Med J. 2003;79:307–312. 10.1136/pmj.79.932.307. [PMC free article] [PubMed] [Google Scholar]

50. Bardella MT, Vecchi M, Conte D, Del Ninno E, Fraquelli M, Pacchetti S, et al. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. Hepatology. 1999;29:654–657. 10.1002/hep.510290318. [PubMed] [Google Scholar]

51. Lo Iacono O, Petta S, Venezia G, Di Marco V, Tarantino G, Barbaria F, et al. Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease? Am J Gastroenterol. 2005;100:2472–2477. 10.1111/j.1572-0241.2005.00244.x. [PubMed] [Google Scholar]

52. Volta U, De Franceschi L, Lari F, Molinaro N, Zoli M, Bianchi FB. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet. 1998;352:26–29. 10.1016/S0140-6736(97)11222-3. [PubMed] [Google Scholar]

53. Farrell RJ, Kelly CP. Diagnosis of celiac sprue. Am J Gastroenterol. 2001;96:3237–3246. 10.1111/j.1572-0241.2001.05320.x. [PubMed] [Google Scholar]

54. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349:474–485. 10.1056/NEJMra021844. [PubMed] [Google Scholar]

55. Fogden E, Neuberger J. Alternative medicines and the liver. Liver Int. 2003;23:213–220. 10.1034/j.1600-0676.2003.00843.x. [PubMed] [Google Scholar]

56. Shad JA, Chinn CG, Brann OS. Acute hepatitis after ingestion of herbs. South Med J. 1999;92:1095–1097. 10.1097/00007611-199911000-00011. [PubMed] [Google Scholar]

57. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2:625–631. 10.1016/S1542-3565(04)00246-0. [PubMed] [Google Scholar]

58. Whitehead MW, Hawkes ND, Hainsworth I, Kingham JG. A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. Gut. 1999;45:129–133. 10.1136/gut.45.1.129. [PMC free article] [PubMed] [Google Scholar]

59. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med. 2000;109:109–113. 10.1016/S0002-9343(00)00461-7. [PubMed] [Google Scholar]

60. Fuchs S, Bogomolski-Yahalom V, Paltiel O, Ackerman Z. Ischemic hepatitis: clinical and laboratory observations of 34 patients. J Clin Gastroenterol. 1998;26:183–186. 10.1097/00004836-199804000-00007. [PubMed] [Google Scholar]

61. Singer AJ, Carracio TR, Mofenson HC. The temporal profile of increased transaminase levels in patients with acetaminophen-induced liver dysfunction. Ann Emerg Med. 1995;26:49–53. 10.1016/S0196-0644(95)70237-7. [PubMed] [Google Scholar]

62. Sellers EM, Freedman F. Treatment of acetaminophen poisoning. Can Med Assoc J. 1981;125:827–829. [PMC free article] [PubMed] [Google Scholar]

63. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31(Suppl 1):9–16. 10.1016/S0168-8278(99)80368-7. [PubMed] [Google Scholar]

64. Wedemeyer H, Jäckel E, Wiegand J, Cornberg M, Manns MP. Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C. Hepatology. 2004;39:1201–1203. 10.1002/hep.20221. [PubMed] [Google Scholar]

65. Roberts EA, Schilsky ML. Division of Gastroenterology and Nutrition, Hospital for Sick Children, Toronto, Ontario, Canada. A practice guideline on Wilson disease. Hepatology. 2003;37:1475–1492. 10.1053/jhep.2003.50252. [PubMed] [Google Scholar]

66. Fortson WC, Tedesco FJ, Starnes EC, Shaw CT. Marked elevation of serum transaminase activity associated with extrahepatic biliary tract disease. J Clin Gastroenterol. 1985;7:502–505. 10.1097/00004836-198512000-00012. [PubMed] [Google Scholar]

67. Anciaux ML, Pelletier G, Attali P, Meduri B, Liguory C, Etienne JP. Prospective study of clinical and biochemical features of symptomatic choledocholithiasis. Dig Dis Sci. 1986;31:449–453. 10.1007/BF01320306. [PubMed] [Google Scholar]

68. Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23:139–142. 10.1034/j.1600-0676.2003.00824.x. [PubMed] [Google Scholar]

69. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291–308. 10.1002/hep.22906. [PubMed] [Google Scholar]

70. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med. 1995;332:924–933. 10.1056/NEJM199504063321406. [PubMed] [Google Scholar]

71. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology. 1999;30:325–332. 10.1002/hep.510300101. [PubMed] [Google Scholar]

72. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–678. 10.1002/hep.23294. [PubMed] [Google Scholar]

Interpretation of liver tests and their disorders

04.10.2018

PDF article

It is not uncommon for a clinician to examine the liver to assess its functional state. The most commonly used indicators for this are alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP) and bilirubin. The measurement of these indicators is traditionally called “liver tests”. Some recommendations of the American College of Gastroenterology (2016) regarding the appointment and interpretation of liver tests are presented in the table.

Hepatocyte damage is usually characterized by a disproportionate increase in AST and ALT against a background of normal or slightly altered ALP; cholestasis, on the contrary, a sharp increase in alkaline phosphatase compared with ALT and AST. As for bilirubin, most of it circulates in the blood in an unconjugated form, and elevated conjugated bilirubin may indicate both hepatocyte damage and cholestasis.

Diagnostic search for laboratory-detected lesions of hepatocytes should include tests for viral hepatitis A, B and C, detection of NAFLD and ALD, screening for hereditary hemochromatosis, autoimmune hepatitis (AIH), Wilson’s disease, α-1-antitrypsin deficiency. The medical history should also be taken into account. With an increase in alkaline phosphatase, it is necessary to diagnose PBC and primary sclerosing cholangitis.

It is important that normal laboratory values ​​are usually defined as the average value in a healthy population ± 2 standard deviations. This definition of the norm covers 95% of people, i.e., in 2.5% of the world’s population, these indicators, by definition, will exceed the norm. The normal levels of ALP and bilirubin differ less in different laboratories, while there is significant variability for ALT.

For example, in one study, 67 laboratories analyzed used an upper limit of normal (ULN) ALT of 31 to 72 U/L. It depends on the equipment of the laboratory, different methods for determining the quantitative indicator of the norm, the characteristics of the population used as healthy.

ALT is a more specific marker of liver damage than AST, but a normal ALT level does not rule out significant liver disease. An increase in AST without a concomitant increase in ALT may indicate damage to the heart or muscles. A borderline increase in AST and/or ALT is considered to be <2×ULN, slight - 2-5×ULN, moderate -5-15 ULN, severe - >15×ULN, and massive – >10,000 IU/L. The diagnostic algorithm at various levels of increase is shown in Figures 1-5.
AP is a member of the family of zinc metalloproteinases that catalyze the hydrolysis of phosphate esters at alkaline pH.

Interestingly, in people with blood type 1 or 2, serum ALP may increase after eating fatty foods, although this metabolic feature is rarely used in practice. The main reasons for the increase in the level of alkaline phosphatase are obstruction of the biliary tract (most often; possibly even in the absence of elevated bilirubin), pregnancy; Also, the level of alkaline phosphatase is increased in children and the elderly, especially in women. With a parallel increase in GGT, it can be concluded that the hepatic cause of the increase in alkaline phosphatase.

Bilirubin, bound to albumin, is formed from the breakdown of old red blood cells and predominantly circulates in unconjugated form. Unconjugated (indirect) bilirubin is not excreted in the urine. In turn, conjugated bilirubin becomes water-soluble and excreted into bile, then converted by intestinal bacteria into urobilinogen, excreted in urine and feces. It is the absence of urobilinogen that gives the feces a discolored appearance in violation of the outflow of bile. Unconjugated bilirubin makes up about 70% of total serum bilirubin.

Determination of bilirubin fractions is especially important when ALT, AST and ALP are in the normal range or slightly changed. If total bilirubin is elevated, mainly due to unconjugated bilirubin, hepatocellular damage is unlikely. An increase in direct bilirubin indicates such lesions or cholestasis.

Liver tests (ALT, AST, ALP, bilirubin) are markers of liver damage, not liver function. Albumin and PTT are indicators of hepatocyte function. Decreased albumin levels (normally ≥3.5 g/dL) usually indicate liver disease lasting ≥3 weeks, although any significant disease can decrease albumin levels due to cytokine exposure. PTT is a more sensitive measure of liver function as it may be elevated in patients with severe liver disease lasting <24 hours.

Of note, albumin, bilirubin, and PTT may be affected by extrahepatic factors. For example, in the presence of vitamin K deficiency and steatorrhea (in the absence of liver disease), cholestasis, or significant hepatocellular dysfunction, PTP lengthens. Treatment with warfarin, heparin bolus administration, disseminated intravascular coagulation syndrome, and hypothermia can also lead to an increase in PTT.

Certain liver diseases

Viral hepatitis B and C

The screening test for chronic hepatitis C is an antibody to the virus with a sensitivity of 92-97%. False positive results are observed in 5% of all cases and in 30% of patients without risk factors. Confirmation of chronic infection is provided by highly sensitive polymerase chain reaction (PCR) with the determination of viral RNA. Individuals with identified RNA should be referred to a specialist for further evaluation of infection and liver fibrosis, and a decision on antiviral therapy.

Acute hepatitis C, accompanied by higher levels of transaminases than chronic, usually occurs without jaundice and other clinical symptoms. The diagnosis of acute hepatitis C can be suspected in the presence of risk factors and confirmed using antibodies to the virus (positive 6-8 weeks after infection) and then by determining the virus RNA by PCR.

Hepatitis B testing should be done in all patients with persistently elevated AST/ALT. Determining the status of infection can be done using three serological tests: HBsAg, indicating the presence of infection; total antibodies to HBcAg, reporting previous exposure to infection or the presence of chronic HBV infection; antibodies to HBsAg, signaling the presence of immunity to this hepatitis that arose as a result of vaccination or a disease transferred in the past.

Chronic infection is confirmed by the presence of HBsAg, antibodies to the core antigen of the virus and / or the determination of viremia using a highly sensitive analysis for the detection of viral DNA. Individuals with chronic hepatitis B should be referred to a hepatologist for further evaluation and a decision on antiviral therapy. The diagnosis of acute hepatitis B is made with a positive test for IgM to HBcAg and the presence of HBsAg. Acute hepatitis B is more often than acute hepatitis C accompanied by clinical symptoms.

NAFLD

NAFLD is an extremely common disease associated with metabolic syndrome. Unlike ALD, there is no unique pattern of changes in ALT and AST for NAFLD, although ALT levels are usually more elevated than AST levels, and levels of both aminotransferases rarely exceed 300 IU/L. Although many individuals with NAFLD suspected of having steatosis on imaging studies may have normal liver tests, the presence of abnormal liver tests indicates a greater likelihood of non-alcoholic steatohepatitis. To establish this diagnosis accurately, a liver biopsy is required, although the role of a non-invasive method for determining the degree of fibrosis and steatosis, elastography, is also increasing.

ABP

Alcohol use is a common cause of elevated liver tests, either alone or in association with chronic liver disease. Specific patterns of changes in liver tests are associated with ALD, in particular the AST:ALT ratio of at least 2:1, and transaminase values ​​rarely exceed 300 IU / L. A further increase in this ratio (3:1, 4:1, etc.) increases the likelihood of ABP. An additional test is the measurement of GGT. All patients with elevated liver tests should be directly asked about alcohol use, recommending that it should be completely discontinued.

Autoimmune liver diseases

Chronic AIH, in which persistently elevated transaminases are noted, can develop in parallel with other autoimmune disorders (hypothyroidism, ulcerative colitis, Sjögren’s syndrome, rheumatoid arthritis, psoriasis). AIH is more common in women than in men (4:1). The characteristic laboratory signs of AIH are the presence of antinuclear antibodies, antismooth muscle antibodies, and less commonly, antirenal and antihepatic microsomal antibodies. The diagnosis of AIH requires histological confirmation with analysis taken from a liver biopsy of a tissue sample.

Drug injuries of the liver

Almost all drugs are associated with at least a minimal risk of elevated liver tests with or without concomitant hepatotoxicity. Among such drugs are antibiotics, antiepileptics, non-steroidal anti-inflammatory drugs, statins, anti-tuberculosis, chemotherapeutic and antiretroviral drugs. It should be noted that although statins are associated with increases in ALT and AST, cases of hepatotoxicity of these agents are rare, even in patients with chronic liver disease. Natural supplements associated with hepatotoxicity include ephedra preparations, green tea extract, and shark cartilage. An online source for information on drug hepatotoxicity is the livertox.nih.gov website. To determine drug damage, treatment should be stopped empirically until ALT/AST normalizes.

PBH

PBC, formerly known as primary biliary cirrhosis, is a rare chronic liver disease that predominantly affects the intralobular bile ducts at a microscopic level. PBC is more common in women than men and is associated with increased fatigue and itching. Laboratory examination reveals elevated alkaline phosphatase with or without elevated bilirubin, as well as the main criterion for diagnosis – a positive analysis for antimitochondrial antibodies (in > 95% of patients).

Other

In patients with jaundice and abdominal pain, a history of previous hepatobiliary disease, including cholelithiasis and inflammatory bowel disease, should be taken. Other extrahepatic causes of abnormal liver function tests include heart failure (congestive hepatopathy), early stages of emphysema, celiac disease, and thyroid disease.

Physical examination findings in patients with abnormal liver tests are usually normal, but some symptoms (jaundice, ascites, splenomegaly, palmar erythema, hepatic encephalopathy) may help confirm the presence of liver disease. In addition, the etiology of the disease can be suspected by specific symptoms. For example, contractures

Dupuytren in combination with an increase in the parotid salivary glands and testicular atrophy may accompany ALD; bronze skin color – hereditary hemochromatosis; severe hepatomegaly – acute viral or alcoholic hepatitis; enlarged nodular liver – a malignant process; right hypochondrium tenderness and a positive Murphy’s sign are hepatobiliary diseases (primarily cholecystitis).

From:
Paul Y. Kwo, Stanley M. Cohen, Joseph K. Lim. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol advance online publication, 20 December 2016; doi:10.1038/ajg.2016.517

Prepared by Larisa Strilchuk

Medical newspaper “Health of Ukraine 21 stories” No. 17 (438), spring 2018

  • Number:
  • Medical newspaper “Health of Ukraine 21 stories” No. 17 (438), spring 2018

07/03/2023

Therapy and Family Medicine100 Years of Novo Nordisk: A Breakthrough in Circulatory Diabetes and Obesity

Tuesday 20, 2023 Light medical company Novo Nordisk held a public international online press briefing.
The ceremony is dedicated to the 100th anniversary of the founding of the company, as well as to the plans and wishes for the next 100 years….

07/02/2023

Therapy and Family MedicinePerspectives of Nanotechnologies in the Treatment of Illness and Other Topical Nutrition in Clinical Medicine

All-Ukrainian scientific symposium “Actual nutrition of clinical medicine” dedicated to the Day of Science. The organizer is the Department of Pharmacology and Internal Medicine of Kharkiv National Medical University. The conference was attended by leading physicians of various medical schools, sharing their advanced knowledge in clinical medicine….

07/02/2023

Therapy and family medicine New potential anticoagulants based on inhibitors of pharyngeal factor XIa

The human hemostasis system has evolved in such a way as to increase the blood supply in a rare state of physiological minds and to quickly respond to the shrinkage of the vessels. However, for some pathological states, the process can be disrupted, and the very occlusion of the judge (removal of obstruction through the thrombus), which means thromboembolism. Thrombosis is caused both in arterial and venous vessels. It treats the development of heart attack, ischemic stroke and deep vein thrombosis. Thromboembolic disease is a serious medical problem and the fourth cause of skin death in the world….

07/01/2023

Therapy and family medicine Painful ulcerative spasm: how to help the patient?

The pain across (BP) of the expansion of the middle of the population of the middle age and the sound of po’yazaniy iz m’azovym spasm, which is indicative of pain, as well as for yoga stamina. M’azovy spasm – tsemimovilne morbid shortness of m’yaziv, as if disrupting the function and causing m’yazovy discord. Therefore, for this jubilation, ring the vicorist relaxants of the skeletal muds of the central hall. Some people use non-steroidal anti-spasmodics. Vtіm, there is a great need for new, better colors for the therapy of the beds, which are covered with spasm of the ulcers ….

When the liver goes wrong: a gastroenterologist named 4 common reasons why ALT and AST are elevated in the blood

  • Health

However, the growth of these main “liver” markers in the blood test does not always indicate problems.

April 25, 2022

Source:
Getty Images

A biochemical blood test is considered one of the main ways to find out if the liver copes with the load of “wrong” nutrition, alcohol, and medication. This will be told by such indicators in the analysis as ALT (alanine aminotransferase) and AST (aspartate aminotransferase) – these liver enzymes are among the first to respond to malfunctions of the organ.

– If there is an increase in both ALT and AST, this means that the liver cells are destroyed and the enzymes from them enter the blood. (…) An increase in AST and ALT means that an inflammatory process is taking place in the liver and its cells are being destroyed. If the indicators are above the norm, you need to contact a gastroenterologist, – gastroenterologist Maria Lopatina wrote in her telegram channel, adding that the upper limits of the norm may differ in different laboratories and one must focus on those established where the analysis was taken.

The doctor named the 4 most common causes of increased liver values.

Chronic viral hepatitis

With an increase in ALT and AST in the blood, viral hepatitis B and C are always excluded first. This is very important, as they can be asymptomatic, while destroying the liver. Mandatory tests: HBsAg – hepatitis B and Anti-HCV – hepatitis C.

Non-alcoholic fatty liver disease

When fatty degeneration of liver cells destroys them, ALT and AST in the blood increase and steatohepatitis develops.

Fatty liver disease is suspected if:

  • Waist circumference ≥94/≥80 cm in men/women;

  • Blood pressure 130/85 mmHg And more, or the person is taking antihypertensive drugs;

  • Fasting glucose level of 5.6 mmol/l or more, or the person is taking hypoglycemic drugs;

  • Serum triglycerides more than 1.7 mmol/l;

  • High-density lipoprotein (HDL) level less than 1.0/1.3 mmol/l in men/women.

Drug-induced liver injury

All drugs that we take by mouth pass through the liver. The more drugs we take, the more likely it is to be damaged. This group includes both herbal preparations and dietary supplements. Liver damage can occur immediately or after several weeks.

Alcohol

According to Russian clinical guidelines, a safe dose for the liver in women is 20 grams of ethanol per day, for men – 40 grams. Regular excess of this dose leads to the development of alcoholic hepatitis and an increase in ALT and AST.

Determining the ethanol content in 100 ml of a drink is very simple: the percentage of alcohol in the drink must be multiplied by 0.8. Thus, 100 ml of 40% vodka contains 40×0.8=32 grams of ethanol, and 100 ml of 12% wine contains 12×0.8=9.6 grams of ethanol.

The doctor specifies that there are other reasons for the increase in ALT and AST in the blood, but these four are the most common.

Read also

When an increase in the indicator is not a cause for alarm

It happens that an increase in the level of “liver” indicators may not be associated with a problem in the work of our main “filter”. According to gastroenterologist Maria Lopatina, this may be the case if only the AST index is elevated.

– AST is found not only in the liver, but also in the heart, muscles, kidneys, brain and pancreas. If AST levels are elevated and ALT is normal, causes that are not related to damage to liver cells should be ruled out. For example, active training for all muscle groups, the doctor clarifies.

But if the liver values ​​are below normal in the blood test, in most cases this is not a cause for serious concern. According to the gastroenterologist, a decrease in their level can occur during pregnancy, starvation and a reduced content of vitamin B6.

What other indicators of a blood test can be used to understand that something is wrong with the liver, read HERE.

Signs of liver problems that can be seen in the mirror

According to doctors, the liver does not hurt in the usual sense of the word, especially at first – the specific symptoms of the disease appear when things have gone too far.